IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients

@article{Wang2008IMPDH1GP,
  title={IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients},
  author={J L Wang and J Yang and Adriana Zeevi and S. A. Webber and Diana Monica Gȋrniţă and Rick Selby and J. Fu and Tariq Shah and Vera Pravica and I. Hutchinson and Gilbert J. Burckart},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2008},
  volume={83}
}
Inosine 5′‐monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate‐limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA). Few variants of the IMPDH1 gene have been reported. The objective of this study was to identify and characterize IMPDH1 variants to determine whether genetic variation contributes to differences in MPA response and toxicity in transplant patients. Seventeen genetic variants were identified in… 
Inosine Monophosphate Dehydrogenase Polymorphisms and Renal Allograft Outcome
TLDR
This study represents the largest cohort of patients with the longest follow-up to date and does not support previous evidence for an association between these IMPDH variants and renal allograft rejection and graft survival.
Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
TLDR
The risk of subclinical acute rejection for recipients who cannot adapt in therapeutic drug monitoring (TDM) of MPA seems to be influenced by IMPDH1 rs2278293 polymorphism, which might help to improve MMF therapy.
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil
TLDR
IMPDH II genotyping may not improve MPA treatment outcome over the first year post-transplantation, in contrast to MPA and calcineurine inhibitor therapeutic drug monitoring and IMPDH I genotypes.
Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation.
  • Wei-jie Cao, Haowen Xiao, He Huang
  • Biology, Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2012
Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism
TLDR
It is reported that the IM PDH type II 3757T>C polymorphism is associated with an increased IMPDH activity in MMF-treated renal transplant patients and explains 8.0% of the interpatient variability in IMPDh activity.
SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients.
TLDR
Results suggest for the first time that carriers of the SLCO1B1*5 allele seem to be protected from MPA-related ADRs.
Impact of SLCO1B3 Polymorphisms on Clinical Outcomes in Lung Allograft Recipients Receiving Mycophenolic Acid
TLDR
It is concluded that hypofunctional SNPs in the SLCO1B3 gene are associated with an increased risk for acute rejection and allograft failure in lung transplant recipients treated with MPA.
Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Pre‐Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation
  • P. Glander, P. Hambach, K. Budde
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2004
TLDR
Determination of IMPDH activity prior to transplantation may help to improve MMF therapy after renal transplantation, and high pre‐transplant IM PDH activity and MMF dose reductions were associated with rejection.
IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance
TLDR
A 9 bp insertion within the IMPDH1 P3 promoter was found in a patient exhibiting severe azathioprine resistance and this in vitro assay suggests the variant promoter has altered function in vivo and consequently may have contributed to the thiopurine resistance observed in this patient.
A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity
TLDR
IMPDH2 has low genetic diversity, but the nonsynonymous variant L263F has a significant impact on inosine 5′-monophosphate dehydrogenase activity.
Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients
TLDR
The MRP2 C-24T and C-3972T polymorphisms protect renal transplant recipients from a decrease in MPA exposure associated with mild liver dysfunction and are suggested to be associated with a lower oral clearance of MPA in steady-state conditions.
The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.
The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation
TLDR
More data are needed to fully establish the meaning of the reported prognostic value of preoperative inosine monophosphate dehydrogenase (IMPDH) activity, and longitudinal studies monitoring IMPDH activity after transplantation are eagerly awaited.
Mycophenolate mofetil and its mechanisms of action.
Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.
TLDR
This analysis of the novel IMPDH1 mutants substantiates previous reports that IM PDH1 mutations do not alter enzyme activity and demonstrates that these mutants alter the recently identified single-stranded nucleic acid binding property of IMPDh.
Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid
TLDR
Several UGT1A8 variants identified may potentially account for the large interindividual variance in MMF pharmacokinetics and deserve further clinical investigations.
Detection of the mycophenolate-inhibited form of IMP dehydrogenase in vivo.
TLDR
It is shown here that de novo synthesis of the IMD2-encoded protein is strongly induced upon MPA treatment and the mobility shift assay could serve as a tool for the detection of drug-inactivated IMPDH in the cells of patients receiving MPA therapy.
...
1
2
3
4
5
...